Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Erratum to: Primary glioblastoma multiforme tumors and recurrence: comparative analysis of the danger signals HMGB1, HSP70, and calreticulin.

Muth C, Rubner Y, Semrau S, Rühle PF, Frey B, Strnad A, Buslei R, Fietkau R, Gaipl US.

Strahlenther Onkol. 2016 Mar;192(3):156. doi: 10.1007/s00066-016-0942-7. No abstract available.

PMID:
26809739
2.

Primary glioblastoma multiforme tumors and recurrence : Comparative analysis of the danger signals HMGB1, HSP70, and calreticulin.

Muth C, Rubner Y, Semrau S, Rühle PF, Frey B, Strnad A, Buslei R, Fietkau R, Gaipl US.

Strahlenther Onkol. 2016 Mar;192(3):146-55. doi: 10.1007/s00066-015-0926-z. Epub 2015 Dec 8. Erratum in: Strahlenther Onkol. 2016 Mar;192(3):156.

PMID:
26646311
3.

Effects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines.

Pasi F, Paolini A, Nano R, Di Liberto R, Capelli E.

Biomed Res Int. 2014;2014:453497. doi: 10.1155/2014/453497. Epub 2014 Jul 1.

4.

Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.

Rubner Y, Muth C, Strnad A, Derer A, Sieber R, Buslei R, Frey B, Fietkau R, Gaipl US.

Radiat Oncol. 2014 Mar 30;9(1):89. doi: 10.1186/1748-717X-9-89.

5.

Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin.

El Mezayen R, El Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR.

Immunol Lett. 2007 Jul 31;111(1):36-44. Epub 2007 May 25.

6.

Temporal and spatial patterns of endogenous danger signal expression after wound healing and in response to lymphedema.

Zampell JC, Yan A, Avraham T, Andrade V, Malliaris S, Aschen S, Rockson SG, Mehrara BJ.

Am J Physiol Cell Physiol. 2011 May;300(5):C1107-21. doi: 10.1152/ajpcell.00378.2010. Epub 2011 Jan 19.

7.

Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release.

Korbelik M, Zhang W, Merchant S.

Cancer Immunol Immunother. 2011 Oct;60(10):1431-7. doi: 10.1007/s00262-011-1047-x. Epub 2011 Jun 5.

PMID:
21644033
8.

Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme.

Raman F, Scribner E, Saut O, Wenger C, Colin T, Fathallah-Shaykh HM.

PLoS One. 2016 Jan 12;11(1):e0146617. doi: 10.1371/journal.pone.0146617. eCollection 2016.

9.

Stimulation of dendritic cells by DAMPs in ALA-PDT treated SCC tumor cells.

Wang X, Ji J, Zhang H, Fan Z, Zhang L, Shi L, Zhou F, Chen WR, Wang H, Wang X.

Oncotarget. 2015 Dec 29;6(42):44688-702. doi: 10.18632/oncotarget.5975.

10.

Glioblastoma multiforme - an overview.

Urbańska K, Sokołowska J, Szmidt M, Sysa P.

Contemp Oncol (Pozn). 2014;18(5):307-12. doi: 10.5114/wo.2014.40559. Epub 2014 Aug 4. Review.

11.

Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade.

Mohapatra G, Bollen AW, Kim DH, Lamborn K, Moore DH, Prados MD, Feuerstein BG.

Genes Chromosomes Cancer. 1998 Mar;21(3):195-206.

PMID:
9523194
12.

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.

Robinson GW, Orr BA, Gajjar A.

BMC Cancer. 2014 Apr 12;14:258. doi: 10.1186/1471-2407-14-258.

13.

Cyclophilin B supports Myc and mutant p53-dependent survival of glioblastoma multiforme cells.

Choi JW, Schroeder MA, Sarkaria JN, Bram RJ.

Cancer Res. 2014 Jan 15;74(2):484-96. doi: 10.1158/0008-5472.CAN-13-0771. Epub 2013 Nov 22.

14.

[GLIOBLASTOMA MULTIFORME--THE PROGRESS OF KNOWLEDGE ON THE PATHOGENESIS OF CANCER].

Wańkowicz P, Nowacki P.

Ann Acad Med Stetin. 2014;60(2):40-3. Review. Polish.

PMID:
26591106
15.

Clonal composition of glioblastoma multiforme.

Berkman RA, Clark WC, Saxena A, Robertson JT, Oldfield EH, Ali IU.

J Neurosurg. 1992 Sep;77(3):432-7.

PMID:
1324297
16.

Fine needle aspiration diagnosis of extracranial glioblastoma multiforme: Case report and review of the literature.

Schultz S, Pinsky GS, Wu NC, Chamberlain MC, Rodrigo AS, Martin SE.

Cytojournal. 2005 Nov 14;2:19.

17.

Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E, Giese T, Aprahamian M, Bour G, Rüffer S, Cziepluch C, Daeffler L, Rommelaere J, Werner J, Raykov Z, Giese NA.

J Virol. 2014 May;88(10):5263-76. doi: 10.1128/JVI.03688-13. Epub 2014 Feb 26.

18.

SIRT1 inhibits releases of HMGB1 and HSP70 from human umbilical vein endothelial cells caused by IL-6 and the serum from a preeclampsia patient and protects the cells from death.

Yin Y, Feng Y, Zhao H, Zhao Z, Yua H, Xu J, Che H.

Biomed Pharmacother. 2017 Apr;88:449-458. doi: 10.1016/j.biopha.2017.01.087. Epub 2017 Jan 22.

PMID:
28122311
19.

Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation.

Roy A, Ganesh G, Sippola H, Bolin S, Sawesi O, Dagälv A, Schlenner SM, Feyerabend T, Rodewald HR, Kjellén L, Hellman L, Åbrink M.

J Biol Chem. 2014 Jan 3;289(1):237-50. doi: 10.1074/jbc.M112.435156. Epub 2013 Nov 20.

20.

Salvage therapy for recurrent glioblastoma multiforme: a multimodal approach combining fluorescence-guided resurgery, interstitial irradiation, and chemotherapy.

Archavlis E, Tselis N, Birn G, Ulrich P, Zamboglou N.

Neurol Res. 2014 Dec;36(12):1047-55. doi: 10.1179/1743132814Y.0000000398. Epub 2014 May 23.

PMID:
24852696

Supplemental Content

Support Center